Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS). Although cognitive impairment (CI) affects a large proportion of MS patients, only few data are available about its prognostic value associated with advanced magnetic resonance imaging (MRI) metrics.
Objectives:
We aimed at investigating the relationship between the early CI and the disease progression over 8-year follow-up in MS patients.
Methods:
We conducted a retrospective 8-year longitudinal study involving 78 patients with relapsing-remitting MS, who completed neuropsychological examination and structural MRI at the time of diagnosis. Each patient was clinically evaluated every 6 months, and cortical thickness was quantified at baseline and at the end of the follow-up. Patients were classified as having normal cognition and mild or severe CI.
Results:
The results show that CI at the time of diagnosis is a good predictor of conversion to definite MS (p < 0.001), disability progression (p < 0.001), as well as of transition to secondary progressive phase (p < 0.001) and of cortical thinning (p < 0.001).
Conclusion:
We confirmed and extended the evidence that early CI might be helpful in the identification of MS patients at high risk of disability progression and poor clinical outcome and should be considered as a marker of most aggressive pathology.
SospedraMMartinR. Immunology of multiple sclerosis. Annu Rev Immunol2005; 23: 683–747.
2.
LassmannH. Axonal and neuronal pathology in multiple sclerosis: What have we learnt from animal models. Exp Neurol2010; 225(1): 2–8.
3.
BobholzJARaoSM. Cognitive dysfunction in multiple sclerosis: A review of recent developments. Curr Opin Neurol2003; 16(3): 283–288.
4.
AmatoMPonzianiGSiracusaG. Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years. Arch Neurol2001; 58(10): 1602–1606.
5.
CalabreseMGajofattoAGobbinF. Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy. Mult Scler2014; 21(5): 580–589.
6.
BenedictRHBZivadinovR. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol2011; 7(6): 332–342.
7.
SaccoRBiseccoACorboD. Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: The role of white matter, gray matter and hippocampus. J Neurol2015; 262(7): 1691–1697.
8.
JonkmanLERosenthalDMSormaniMP. Gray matter correlates of cognitive performance differ between relapsing-remitting and primary-progressive multiple sclerosis. PLoS One2015; 10(10): e0129380.
9.
HarrisonDMRoySOhJ. Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis. JAMA Neurol2015; 72(9): 1004–1012.
10.
GeurtsJJGCalabreseMFisherE. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol2012; 11(12): 1082–1092.
11.
CalabreseMAgostaFRinaldiF. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol2009; 66(9): 1144–1150.
12.
CalabreseMPorettoVFavarettoA. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain2012; 135(Pt 10): 2952–2961.
13.
CalabreseMReynoldsRMagliozziR. Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients. PLoS One2015; 10(8): e0135428.
14.
ZipoliVGorettiBHakikiB. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler2010; 16(1): 62–67.
15.
DeloireMRuetAHamelD. Early cognitive impairment in multiple sclerosis predicts disability outcome several years later. Mult Scler2010; 16(5): 581–587.
16.
MocciaMLanzilloRPalladinoR. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler2016; 22: 659–667.
17.
PortaccioEStromilloMLGorettiB. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology2009; 73(7): 498–503.
18.
PolmanCHReingoldSCEdanG. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.”Ann Neurol2005; 58(6): 840–846.
19.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
20.
GroupES. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet1998; 352: 1491–1497.
PanitchHMillerAPatyD. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology2004; 63(10): 1788–1795.
23.
BeckATSteerRABrownGK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996, pp. 1–82.
24.
AmatoMPPortaccioEGorettiB. The Rao’s brief repeatable battery and stroop test: Normative values with age, education and gender corrections in an Italian population. Mult Scler2006; 12(6): 787–793, http://www.ncbi.nlm.nih.gov/pubmed/17263008
25.
PhamDLPrinceJL. Adaptive fuzzy segmentation of magnetic resonance images. IEEE Trans Med Imaging1999; 18: 737–752.
26.
CalabreseMRinaldiFGrossiP. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler2010; 16(10): 1220–1228.
27.
FischlBDaleAM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A2000; 97(20): 11050–11055.
28.
HartikainenPRäsänenJJulkunenV. Cortical thickness in frontotemporal dementia, mild cognitive impairment, and Alzheimer’s disease. J Alzheimers Dis2012; 30(4): 857–874.
29.
FilippiMPreziosaPCopettiM. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology2013; 81(20): 1759–1767.
30.
RoccaMAAmatoMPDe StefanoN. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol2015; 14(3): 302–317.
31.
LangdonDW. Cognition in multiple sclerosis. Curr Opin Neurol2011; 24(3): 244–249.
32.
ErlangerDMKaushikTCarusoLS. Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial. J Neurol Sci2014; 340(1): 123–129.
33.
StroberLEnglertJMunschauerF. Sensitivity of conventional memory tests in multiple sclerosis: Comparing the Rao brief repeatable neuropsychological battery and the minimal assessment of cognitive function in MS. Mult Scler2009; 15(9): 1077–1084.
34.
BenedictRHAmatoMBoringaJ. Brief International Cognitive Assessment for MS (BICAMS): International standards for validation. BMC Neurol2012; 12(1): 55.
35.
GreerJMMcCombePA. Role of gender in multiple sclerosis: Clinical effects and potential molecular mechanisms. J Neuroimmunol2011; 234(1–2): 7–18.
